1. Home
  2. VS vs NXL Comparison

VS vs NXL Comparison

Compare VS & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Versus Systems Inc.

VS

Versus Systems Inc.

HOLD

Current Price

$1.48

Market Cap

7.3M

Sector

Technology

ML Signal

HOLD

Logo Nexalin Technology Inc.

NXL

Nexalin Technology Inc.

HOLD

Current Price

$0.52

Market Cap

7.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VS
NXL
Founded
2013
2010
Country
United States
United States
Employees
5
8
Industry
EDP Services
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.3M
7.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
VS
NXL
Price
$1.48
$0.52
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
29.5K
780.0K
Earning Date
04-15-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$15.52
Revenue Next Year
N/A
$100.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.75
$0.31
52 Week High
$2.81
$2.00

Technical Indicators

Market Signals
Indicator
VS
NXL
Relative Strength Index (RSI) 61.24 60.15
Support Level $1.10 $0.36
Resistance Level $1.56 $0.66
Average True Range (ATR) 0.16 0.08
MACD 0.04 0.01
Stochastic Oscillator 66.31 63.79

Price Performance

Historical Comparison
VS
NXL

About VS Versus Systems Inc.

Versus Systems Inc operates within the technology sector, focusing on engagement-enhancing solutions through its proprietary prizing and promotions platform. This technology enables developers and content creators across streaming, live events, broadcast, gaming, and other media to integrate real-world prizes into their experiences, fostering greater consumer interaction and providing a compelling opportunity for brand partners and advertisers. The company operates in Canada and the USA.

About NXL Nexalin Technology Inc.

Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

Share on Social Networks: